Epoetin Alfa — Discount Pricing

Other medications in Blood Disorders

• Factor IX
• Factor VIII
• Filgrastim
• Hydroxyurea
• L-Glutamine
• Luspatercept
• Pegfilgrastim
• Romiplostim

About Epoetin Alfa

Epoetin alfa is a critical medication designed to help your body produce more red blood cells, effectively treating certain types of anemia. For those managing chronic health conditions, the cost of such vital treatments can be a significant burden. TheDrugClub is committed to making essential medications like epoetin alfa accessible and affordable, ensuring you can focus on your health without financial worry.

What is Epoetin Alfa and What Does It Treat?

Epoetin alfa is a medication primarily used to treat anemia, a condition where your blood lacks healthy red blood cells. This can lead to fatigue, shortness of breath, and other debilitating symptoms. Specifically, epoetin alfa is prescribed for anemia caused by chronic kidney disease, chemotherapy for certain cancers, treatment with zidovudine in HIV-infected patients, and to reduce the need for blood transfusions in certain surgical patients. By addressing the root cause of low red blood cell count, it helps improve energy levels and overall quality of life.

How Does Epoetin Alfa Work?

Epoetin alfa is a synthetic version of erythropoietin, a natural hormone produced by your kidneys. Erythropoietin plays a crucial role in stimulating the bone marrow to produce red blood cells. When your body isn't producing enough of this hormone—due to kidney disease or other conditions—or when red blood cells are being destroyed faster than they can be made (as with some chemotherapy regimens), anemia develops. Epoetin alfa steps in to mimic the action of natural erythropoietin, signaling your bone marrow to ramp up red blood cell production, thereby increasing your red blood cell count and improving your body's ability to carry oxygen.

Understanding Typical Costs

As a biologic medication, epoetin alfa can be quite expensive. Without insurance, or with high deductibles and co-insurance, a single dose can cost hundreds of dollars, and monthly treatments can easily run into thousands. These costs can be a major barrier for patients needing consistent, long-term treatment. The financial strain can lead to missed doses or discontinued treatment, which can have serious health consequences. This is where finding a reliable and affordable solution becomes incredibly important for patient well-being.

TheDrugClub: Your Solution for $0 Co-Pay and Free Home Delivery

At TheDrugClub, we believe that managing your health shouldn't break the bank. For our members, accessing vital medications like epoetin alfa is made simple and affordable. We offer epoetin alfa with a $0 co-pay, completely eliminating the

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Epoetin Alfa is approved for (FDA label)

Epogen is an erythropoiesis-stimulating agent (ESA) indicated for: Treatment of anemia due to: - Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis ( 1.1 ). - Zidovudine in patients with Human Immunodeficiency Virus (HIV) infection ( 1.2 ). - The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy ( 1.3 ). Reduction of allogeneic red blood cell (RBC) transfusions in patients undergoing elective, noncardiac, nonvascular surgery ( 1.4 ). Limitations of Use Epogen has not been shown to improve quality of life, fatigue, or patient well-being ( 1.5 ).

Source: Read the full FDA label on DailyMed. Label effective date: June 23, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Epoetin Alfa (FDA label)

WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE Chronic Kidney Disease: In controlled trials, patients with chronic kidney disease (CKD) experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL [see Warnings and Precautions ( 5.1 )] . No trial has identified a hemoglobin target level, E SA dose, or dosing strategy that does not increase these risks [see Dosage and Administration ( 2.2 )] . Use the lowest Epogen dose sufficient to reduce the need for red blood cell (RBC) transfusions [see Warnings and Precautions ( 5.1 )] . Cancer: ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers [see Warnings and Precautions ( 5.2 )] . To decrease these risks, as well as the risk of serious cardiovascular and thromboembolic reactions, use the lowest dose needed to avoid RBC transfusions [see Dosage and Administration ( 2.4 )] . Use ESAs only for anemia from myelosuppressive chemotherapy [see Indications and Usage ( 1.3 )] . ESAs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure [see Indications and Usage ( 1.5 )] . Discontinue following the completion of a chemotherapy course [see Dosage and Administration ( 2.4 )] . Perisurgery: Due to increased risk of Deep Venous Thrombosis (DVT), DVT prophylaxis is recommended [see Dosage and Administration ( 2.5 ), Warnings and Precautions ( 5.1 )] . WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE See full prescribing information for complete boxed warning.

Source: FDA prescribing information (DailyMed). Set ID: 1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5. SPL document ID: bf994196-5149-4089-b1fc-c4f0cb8744b3. Label effective date: June 23, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Epoetin Alfa (FDA label)

Injection: 2,000 Units/mL, 3,000 Units/mL, 4,000 Units/mL, and 10,000 Units/mL of Epogen as a clear and colorless liquid in single-dose vials. 20,000 Units/2 mL (10,000 Units/mL) and 20,000 Units/mL of Epogen as a clear and colorless liquid in multiple-dose vials (contains benzyl alcohol). Injection 2,000 Units/mL, 3,000 Units/mL, 4,000 Units/mL, and 10,000 Units/mL in single-dose vials ( 3 ) 20,000 Units/2 mL (10,000 Units/mL) and 20,000 Units/mL in multiple-dose vials containing benzyl alcohol ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5. SPL document ID: bf994196-5149-4089-b1fc-c4f0cb8744b3. Label effective date: June 23, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Epoetin Alfa (FDA label)

The following serious adverse reactions are discussed in greater detail in other sections of the label: Increased Mortality, Myocardial Infarction, Stroke, and Thromboembolism [see Warnings and Precautions ( 5.1 )] Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence in Patients with Cancer [see Warnings and Precautions ( 5.2 )] Hypertension [see Warnings and Precautions ( 5.3 )] Seizures [see Warnings and Precautions ( 5.4 )] PRCA [see Warnings and Precautions ( 5.6 )] Serious Allergic Reactions [see Warnings and Precautions ( 5.7 )] Severe Cutaneous Reactions [see Warnings and Precautions ( 5.8 )] Patients with CKD: Adverse reactions in ≥ 5% of Epogen-treated patients in clinical studies were hypertension, arthralgia, muscle spasm, pyrexia, dizziness, medical device malfunction, vascular occlusion, and upper respiratory tract infection ( 6.1 ).

Source: FDA prescribing information (DailyMed). Set ID: 1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5. SPL document ID: bf994196-5149-4089-b1fc-c4f0cb8744b3. Label effective date: June 23, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Epoetin Alfa (FDA label)

Epogen is contraindicated in patients with: Uncontrolled hypertension [see Warnings and Precautions ( 5.3 )] Pure red cell aplasia (PRCA) that begins after treatment with Epogen or other erythropoietin protein drugs [see Warnings and Precautions ( 5.6 )] Serious allergic reactions to Epogen [see Warnings and Precautions ( 5.7 )] Epogen from multiple-dose vials contains benzyl alcohol and is contraindicated in: Neonates, infants, pregnant women, and lactating women [see Warnings and Precautions ( 5.9 ), Use in Specific Populations ( 8.1 , 8.2 , 8.4 )] . Uncontrolled hypertension ( 4 ) Pure red cell aplasia (PRCA) that begins after treatment with Epogen or other erythropoietin protein drugs ( 4 ) Serious allergic reactions to Epogen ( 4 ) Use of the multiple-dose vials containing benzyl alcohol in neonates, infants, pregnant women, and lactating women ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5. SPL document ID: bf994196-5149-4089-b1fc-c4f0cb8744b3. Label effective date: June 23, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Epoetin Alfa (FDA label)

Increased Mortality, Myocardial Infarction, Stroke, and Thromboembolism: Using ESAs to target a hemoglobin level of greater than 11 g/dL increases the risk of serious adverse cardiovascular reactions and has not been shown to provide additional benefit ( 5.1 and 14.1 ). Use caution in patients with coexistent cardiovascular disease and stroke ( 5.1 ). Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence in Patients with Cancer ( 5.2 ). Hypertension: Control hypertension prior to initiating and during treatment with Epogen ( 5.3 ). Seizures: Epogen increases the risk for seizures in patients with CKD ( 5.4 ). Increase monitoring of these patients for changes in seizure frequency or premonitory symptoms ( 5.4 ). PRCA: If severe anemia and low reticulocyte count develop during Epogen treatment, withhold Epogen and evaluate for PRCA ( 5.6 ). Serious Allergic Reactions: Discontinue Epogen and manage reactions ( 5.7 ).

Source: FDA prescribing information (DailyMed). Set ID: 1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5. SPL document ID: bf994196-5149-4089-b1fc-c4f0cb8744b3. Label effective date: June 23, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.